


S T O P C



Surveillance and Treatment of Prisoners with Hepatitis C

Professor Greg Dore | Wednesday 16 September 2015

Australian Prison Population



- Overall prison population - 30% HCV prevalence
- PWID in prison – 60% prevalence, 10-15% annual transmission

Current prevention strategies


No preventative vaccine

Hepatitis C Incidence and Transmission in Prisons (HITS-p)
 49% reported injecting drug use in follow-up
 31% reported sharing apparatus

Limited harm reduction


No needle and syringe programs

HCV Antibody Prevalence in Prisoners (2010)




2013 National Prison Entrants' BBV and Risk Behaviour Survey

HCV Testing & Treatment in Prisoners (2013)



Mina M et al, Int J of Prisoner of Prisoner Health. In Press.

HCV Treatment Strategies (Australia)




Dore GJ. MJA 2012

NSW Infrastructure

	Total number of prisons	Number of prisons with hepatitis services	Specialist physician - prison based	Specialist physician - hospital based	Hepatitis nurse	General nurse	GP	Psychiatrist	Psychologist	Mental health nurse	D&A counsellor
NSW	31	31	✓	✓	✓	✓	✓	✓	✓	✓	✓
VIC	14	3	✓	✓	✓	✓	✓	✓	✓	✓	✓
QLD	11	8	✓	✓	✓	✓	✓	✓	✓	✓	✓
SA	8	8	✓	✓	✓	✓	✓	✓	✓	✓	✓
WA	16	9	✓	✓	✓	✓	✓	✓	✓	✓	✓
TAS	7	7	✓	✓	✓	✓	✓	✓	✓	✓	✓
NT	5	3	✓	✓	✓	✓	✓	✓	✓	✓	✓
ACT	2	2	✓	✓	✓	✓	✓	✓	✓	✓	✓

Mina M et al. Int J of Prisoner of Prisoner Health. In Press.

NSW Nurse-Led Model of Care (NMLC)




Lloyd A. et al. Clinical Infectious Diseases 2013

SToP-C Goals




- To evaluate the impact of rapid scale-up of DAA treatment on incidence and prevalence of HCV infection in the prison setting
- To develop a translational framework for subsequent establishment of treatment-as-prevention programs in the prison sector

Study Design



SToP-C Network



Study Components

HCV incidence and prevalence phase

- 6-monthly testing and risk behaviour interview

Treatment phase

- DAA therapy for all infected prisoners

Modelling

- Treatment sample size and epidemiological impact

Cost-effectiveness and budget impact

- Is DAA therapy in prisons good value for money and can we afford it?


Qualitative research

- Patient & provider attitudes & barriers towards DAA therapy in prisons

Implementation toolkit

- How can DAA therapy be scaled up across NSW and nationally?

Current Status, Surveillance Phase (at 10 Sep 2015)



Site	Enrolment (n)	Follow-up (n)
Goulburn Correctional Centre	304	78
Lithgow Correctional Centre	55	0
TOTAL	359	78

Treatment Phase - 2016

- All prisoners with HCV infection eligible
- 12-week directly acting antiviral (DAA) therapy (sofosbuvir/velpatasvir)
- One fixed-dose tablet once daily
- >90% cure anticipated
- Minimal side-effects
- Monitor re-infection rates and re-treat



Education and Promotion

- Prison staff (custodial and health) information sessions
- Resources for prisoners and family
 - Video
 - Posters
 - Booklet



Project Partners and Stakeholders



Acknowledgements



SToP-C Protocol Steering Committee

Name	Affiliation
Shaun Lonsdale (Chair)	Hepatitis NSW
Greg Dore	The Kirby Institute, University of New South Wales
Andrew Lloyd	The University of New South Wales
Jason Grady	The Kirby Institute, University of New South Wales
Tony Butler	The Kirby Institute, University of New South Wales
Marianne Byrne	The Kirby Institute, University of New South Wales
Carla Treloar	Centre for Social Research in Health, University of New South Wales
Ian Trewhan	Justice Health & Forensic Mental Health Network
Denise Monkley	Justice Health & Forensic Mental Health Network
Julia Bowman	Justice Health & Forensic Mental Health Network
Ray Donnelly	Justice Health & Forensic Mental Health Network
Luke Grant	Corrective Services NSW
Terry Murrell	Corrective Services NSW
Nicky Bath	NSW Health
Sallie Cairnduff	AH&MRC
Allison Churchill	Community Restorative Centre
Kate Pincock	Community Restorative Centre
Mary Ellen Harrod	NSW Users and AIDS Association
Natasha Martin	University of California San Diego
Peter Vickerman	University of Bristol
Georgina Chambers	The University of New South Wales

SToP-C is supported by funding from the Commonwealth Department of Health and Ageing through a NH&MRC Partnership Project grant, Gilead Sciences Inc, and in-kind support from all project partners.